{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:25:10Z","timestamp":1787847910166,"version":"build-2784847793"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Programmed cell death-1 checkpoint inhibitors have significantly improved cancer survival outcomes. More than half of patients on programmed cell death-1 checkpoint inhibitors develop cutaneous immune-related complications. The prognostic significance of eruptions biopsied in routine clinical practice remains underexplored. We aimed to characterize biopsy-confirmed cutaneous toxicities associated with checkpoint inhibitors and assess their association with survival. We conducted a retrospective study of biopsy-confirmed checkpoint inhibitor\u2013associated dermatoses at our single institution between September 2014 and June 2025, analyzing clinical features, histopathology, treatment outcomes, and progression-free (PFS) and overall survival. Seventy-five patients were included (mean age 67.0 years [24, 95]; 52% female). Most developed reactions within 6 months of initiating therapy. Most took pembrolizumab and nivolumab. Histopathologic categories included type IV hypersensitivity (T4HS) lichenoid (N = 29; 39%), T4HS eczematoid (N = 10; 13%), other T4HS patterns (N = 6; 8%) including 1 fatal case of toxic epidermal necrolysis, vesiculobullous (N = 12; 16%), psoriasis (N = 4; 5%), reversible epitheliotropic T-cell dyscrasia (N = 4; 5%), sclerodermoid (N = 4; 5%), Sweet syndrome (N = 3; 4%), and miscellaneous (N = 3; 4%). Most eruptions improved or remained stable with treatment with 1 fatal case of toxic epidermal necrolysis. Patients with T4HS-mediated reaction, 60% of our cohort, had reduced tumor progression hazard with longer PFS (hazard ratio = 0.49 [0.23\u20131.05],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.07; PFS-p\n                    <jats:sub>adj<\/jats:sub>\n                    = 0.06, PFS-late-weighted p\n                    <jats:sub>adj<\/jats:sub>\n                    = 0.04). Overall survival did not differ. Our study is limited by sample size. Checkpoint inhibitor\u2013associated dermatoses resemble established standard cutaneous adaptive B- and T-cell\u2013driven dermatoses. Regulatory T-cell inhibition, allowing emergence of autoreactive B and T cells or unmasking of subclinical hypersensitivity, is likely pathogenetically key.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000003406","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:00:08Z","timestamp":1787846408000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Biopsied Cutaneous Adverse Effects of PD-1 and PD-L1 Checkpoint Inhibitors and Progression-free Survival: A Retrospective Case Series of 75 Patients"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8103-0329","authenticated-orcid":false,"given":"Julian D. S.","family":"Willett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor A.","family":"Kalomeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Del Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"R1-20260827","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","article-title":"Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Sci Rep."},{"key":"R2-20260827","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer."},{"key":"R3-20260827","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of Anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"R4-20260827","doi-asserted-by":"crossref","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol."},{"key":"R5-20260827","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"R6-20260827","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"key":"R7-20260827","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamadermatol.2025.0025","article-title":"Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors","volume":"161","author":"Fletcher","year":"2025","journal-title":"JAMA Dermatol."},{"key":"R8-20260827","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin Cancer Res."},{"key":"R9-20260827","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/09546634.2021.1898529","article-title":"Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses","volume":"33","author":"Le","year":"2022","journal-title":"J Dermatolog Treat."},{"key":"R10-20260827","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol."},{"key":"R11-20260827","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jaad.2024.08.021","article-title":"Erythema multiforme associated with the immune checkpoint inhibitors: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System","volume":"91","author":"Godfrey","year":"2024","journal-title":"J Am Acad Dermatol."},{"key":"R12-20260827","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2024.10.004","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome-like reaction: an atypical clinical presentation","volume":"54","author":"Mahajan","year":"2024","journal-title":"JAAD Case Rep."},{"key":"R13-20260827","doi-asserted-by":"crossref","first-page":"1414136","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol."},{"key":"R14-20260827","doi-asserted-by":"crossref","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R15-20260827","doi-asserted-by":"crossref","first-page":"20038","DOI":"10.1038\/s41598-022-24286-3","article-title":"Cutaneous adverse events in patients treated with PD-1\/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Sci Rep."},{"key":"R16-20260827","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/dermatopathology10030033","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic adrenocortical cancer: a case report and literature review","volume":"10","author":"Madan","year":"2023","journal-title":"Dermatopathology (Basel)"},{"key":"R17-20260827","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jdin.2023.11.013","article-title":"Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level","volume":"15","author":"Meier-Schiesser","year":"2024","journal-title":"JAAD Int."},{"key":"R18-20260827","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"R19-20260827","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/0284186X.2021.1878387","article-title":"Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community","volume":"60","author":"Ngo","year":"2021","journal-title":"Acta Oncol."},{"key":"R20-20260827","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"R21-20260827","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B: Stat Methodol."},{"key":"R22-20260827","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"2012","journal-title":"J Am Stat Assoc."},{"key":"R24-20260827","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B: Stat Methodol."},{"key":"R25-20260827","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0091-6749(99)70489-6","article-title":"Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity","volume":"103","author":"Kalish","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"R26-20260827","doi-asserted-by":"crossref","first-page":"1081256","DOI":"10.3389\/fimmu.2023.1081256","article-title":"The roles of T cells in psoriasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol."},{"key":"R27-20260827","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer."},{"key":"R28-20260827","doi-asserted-by":"crossref","first-page":"597761","DOI":"10.3389\/fimmu.2021.597761","article-title":"The roles of immunoregulatory networks in severe drug hypersensitivity","volume":"12","author":"Hsu","year":"2021","journal-title":"Front Immunol."},{"key":"R29-20260827","doi-asserted-by":"crossref","first-page":"1689519","DOI":"10.3389\/fonc.2025.1689519","article-title":"Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol."},{"key":"R30-20260827","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ijd.70061","article-title":"Cutaneous immune-related adverse events and efficacy of immune checkpoint inhibitors for patients with advanced solid organ malignancies","volume":"65","author":"O'Reilly","year":"2026","journal-title":"Int J Dermatol."},{"key":"R31-20260827","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3389\/fimmu.2019.01389","article-title":"Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering","volume":"10","author":"Hubner","year":"2019","journal-title":"Front Immunol."},{"key":"R32-20260827","doi-asserted-by":"crossref","first-page":"104985","DOI":"10.1016\/j.ebiom.2024.104985","article-title":"High-dimensional profiling of regulatory T cells in psoriasis reveals an impaired skin-trafficking property","volume":"100","author":"Lee","year":"2024","journal-title":"EBioMedicine"},{"key":"R33-20260827","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory T cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front Immunol."},{"key":"R34-20260827","doi-asserted-by":"crossref","first-page":"103185","DOI":"10.1016\/j.autrev.2022.103185","article-title":"T cell abnormalities in systemic sclerosis","volume":"21","author":"Jin","year":"2022","journal-title":"Autoimmun Rev."},{"key":"R35-20260827","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fimmu.2018.00786","article-title":"Targeting regulatory T cells to treat patients with systemic lupus erythematosus","volume":"9","author":"Mizui","year":"2018","journal-title":"Front Immunol."},{"key":"R36-20260827","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2019.00414","article-title":"Insights into the pathogenesis of Sweet's syndrome","volume":"10","author":"Heath","year":"2019","journal-title":"Front Immunol."},{"key":"R37-20260827","doi-asserted-by":"crossref","first-page":"102661","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun Rev."},{"key":"R38-20260827","first-page":"e15548","article-title":"Radiation recall dermatitis in patients treated with immune checkpoint inhibitors: a case report and literature review","volume":"13","author":"Yigit","year":"2021","journal-title":"Cureus"},{"key":"R39-20260827","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.iac.2017.07.007","article-title":"Severe delayed drug reactions: role of genetics and viral infections","volume":"37","author":"Pavlos","year":"2017","journal-title":"Immunol Allergy Clin North Am."},{"key":"R40-20260827","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol."},{"key":"R41-20260827","first-page":"100506","article-title":"A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution","volume":"30","author":"Masterson","year":"2022","journal-title":"Cancer Treat Res Commun."},{"key":"R42-20260827","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/jid.2008.242","article-title":"T-cell-mediated injury to keratinocytes: insights from animal models of the lichenoid tissue reaction","volume":"129","author":"Dutz","year":"2009","journal-title":"J Invest Dermatol."},{"key":"R43-20260827","doi-asserted-by":"crossref","first-page":"7645465","DOI":"10.1155\/2018\/7645465","article-title":"Adverse immunologically mediated oral mucosal reactions to systemic medication: lichenoid tissue reaction\/interface dermatitis-stomatitis, autoimmune vesiculobullous disease, and IgE-dependent and immune complex reactions","volume":"2018","author":"Khammissa","year":"2018","journal-title":"J Immunol Res."},{"key":"R44-20260827","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1111\/1346-8138.15461","article-title":"Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma","volume":"47","author":"Okada","year":"2020","journal-title":"J Dermatol."},{"key":"R45-20260827","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1111\/1346-8138.16006","article-title":"Lichen planus pemphigoides with antibodies against the BP180 C-terminal domain induced by pembrolizumab in a melanoma patient","volume":"48","author":"Yoshida","year":"2021","journal-title":"J Dermatol."},{"key":"R46-20260827","first-page":"742","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma","volume":"15","author":"Schmidgen","year":"2017","journal-title":"J Dtsch Dermatol Ges."},{"key":"R47-20260827","doi-asserted-by":"crossref","first-page":"e15432","DOI":"10.1111\/dth.15432","article-title":"Lichen planus pemphigoides: a unique form of bullous and lichenoid eruptions secondary to nivolumab","volume":"35","author":"Shah","year":"2022","journal-title":"Dermatol Ther."},{"key":"R48-20260827","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/derm.2022.0019","article-title":"Immune checkpoint inhibitor-induced Lichen Planus pemphigoides: report of two cases","volume":"34","author":"Hagstrom","year":"2023","journal-title":"Dermatitis"},{"key":"R49-20260827","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/all.12184","article-title":"Immunology of atopic eczema: overcoming the Th1\/Th2 paradigm","volume":"68","author":"Eyerich","year":"2013","journal-title":"Allergy"},{"key":"R50-20260827","doi-asserted-by":"crossref","first-page":"1485594","DOI":"10.3389\/fonc.2024.1485594","article-title":"Cutaneous adverse events due to checkpoint inhibitors - a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022","volume":"14","author":"Furrer-Matcau","year":"2024","journal-title":"Front Oncol."},{"key":"R51-20260827","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.jaip.2023.06.008","article-title":"Nivolumab-induced Stevens-Johnson syndrome: not only due to PD-1 inhibition","volume":"11","author":"Rodriguez-Otero","year":"2023","journal-title":"J Allergy Clin Immunol Pract."},{"key":"R52-20260827","doi-asserted-by":"crossref","first-page":"10733","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun."},{"key":"R53-20260827","doi-asserted-by":"crossref","first-page":"1421684","DOI":"10.3389\/fimmu.2024.1421684","article-title":"Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study","volume":"15","author":"He","year":"2024","journal-title":"Front Immunol."},{"key":"R54-20260827","doi-asserted-by":"crossref","first-page":"625667","DOI":"10.3389\/fimmu.2021.625667","article-title":"The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol."},{"key":"R55-20260827","doi-asserted-by":"crossref","first-page":"7692024","DOI":"10.1155\/2016\/7692024","article-title":"T helper cell subsets in clinical manifestations of psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J Immunol Res."},{"key":"R56-20260827","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol."},{"key":"R57-20260827","doi-asserted-by":"crossref","first-page":"e003066","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer."},{"key":"R58-20260827","doi-asserted-by":"crossref","first-page":"100375","DOI":"10.1016\/j.xjidi.2025.100375","article-title":"Tape strip profiling of checkpoint inhibitor-associated dermatitis highlights pan-T-cell activation: a pilot study","volume":"5","author":"Powers","year":"2025","journal-title":"JID Innov."},{"key":"R59-20260827","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10875-013-9898-x","article-title":"Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis","volume":"33","author":"Tsurikisawa","year":"2013","journal-title":"J Clin Immunol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:00:15Z","timestamp":1787846415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003406","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}